Assessing the potential of gastroretentive technology for gastric cancer targeting

Abstract

Gastric cancer is a multifactorial disease and a major cause of mortality across the globe. Initially, gastric cancer reveals no related symptoms; therefore, patients come to the notice of the clinicians only in advanced stages. Chemotherapy, radiation, surgery, immunotherapy, etc. are some of the common treatment interventions for stomach cancer. Traditional oral chemotherapy reveals several limitations, including inadequate oral bioavailability, repeated dosage, low solubility, short gastric residence period, etc. To address these issues, unique technological advancements recognized as gastroretentive drug delivery system (GRDDS) have been explored by scientists globally. The GRDDS has acquired tremendous significance in the avenue of oral drug delivery. This is a frequently utilized and encouraging methodology of retaining the dosage form in the stomach for a prolonged time and slowly releasing the drug, which can address many of the problems associated with traditional oral delivery. The current review addresses the causes of gastric cancer, significant insights, and classification along with treatment strategies for gastric cancer. Advancements in gastroretentive technology in the treatment of stomach cancer are also focused in the present paper.

Herbal bioactive encapsulated nano-formulations for the treatment of gastric cancer: a concise review

“…The early stage is restricted to mucosa and submucosa, in middle stage, the tumour extends beyond submucosa in the muscular layer. Likewise, in the advanced-stage, tumour reaches up to the subserosa or even beyond it and infiltrates the neighbouring organs [1,2]. Figure 1 represents different stages of gastric cancer and its progression at cellular level.…”